Journal of Postgraduate Medicine, Education and Research

Register      Login

VOLUME 55 , ISSUE 1 ( January-March, 2021 ) > List of Articles

REVIEW ARTICLE

Nonalcoholic Fatty Liver Disease and Obesity

Arka De, Ajay Duseja

Keywords : Hepatic steatosis, Metabolic dysfunction-associated fatty liver disease, Metabolic syndrome, Nonalcoholic fatty liver disease, Nonalcoholic steatohepatitis,Fatty liver

Citation Information : De A, Duseja A. Nonalcoholic Fatty Liver Disease and Obesity. J Postgrad Med Edu Res 2021; 55 (1):27-35.

DOI: 10.5005/jp-journals-10028-1430

License: CC BY-NC 4.0

Published Online: 01-03-2021

Copyright Statement:  Copyright © 2021; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

The ability of the body to store energy in adipose tissue for utilization during exigency has helped us cope with periodic food shortages through much of human history. The easy availability of calorie-dense food and a sedentary lifestyle has, however, resulted in this becoming a bane with adverse health consequences. Both obesity and nonalcoholic fatty liver disease (NAFLD) are lifestyle diseases that have emerged as substantial public health problems globally and in India. Obesity is an important risk factor for NAFLD and its severe form of nonalcoholic steatohepatitis (NASH). Weight loss is the only proven beneficial intervention in NAFLD/NASH. This provides a unique opportunity for managing NASH in obese patients. Lifestyle interventions including dietary modifications and exercise should be the primary modality for weight loss and have shown to be feasible and effective in obese patients with NASH. Although not yet indicated for the management of NASH per se, anti-obesity drugs and bariatric procedures may be considered in selected patients if otherwise indicated and may lead to indirect hepatic benefits secondary to weight loss.


PDF Share
  1. González-Muniesa P, Mártinez-González MA, Hu FB, et al. Obesity. Nat Rev Dis Primers 2017(1):3. DOI: 10.1038/nrdp.2017.34.
  2. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology 2018;67(1):328–357. DOI: 10.1002/hep.29367.
  3. Younossi ZM. Non-alcoholic fatty liver disease – a global public health perspective. J Hepatol 2019;70(3):531–544. DOI: 10.1016/j.jhep.2018.10.033.
  4. Bedogni G, Miglioli L, Masutti F, et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the dionysos nutrition and liver study. Hepatology 2005;42(1):44–52. DOI: 10.1002/hep.20734.
  5. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64(1):73–84. DOI: 10.1002/hep.28431.
  6. Duseja A, Chalasani N. Epidemiology and risk factors of nonalcoholic fatty liver disease (NAFLD). Hepatol Int 2013;7(S2):755–764. DOI: 10.1007/s12072-013-9480-x.
  7. Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44(4):865–873. DOI: 10.1002/hep.21327.
  8. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic associated fatty liver disease: an international expert consensus statement. J Hepatol 2020;73(1):202–209. DOI: 10.1016/j.jhep.2020.03.039.
  9. Duseja A, Taneja S. Changing nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease – not only premature but also confusing. J Clin Exp Hepatol 2020. DOI: 10.1016/j.jceh.2020.08.002.
  10. Mitra S, De A, Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases. Transl Gastroenterol Hepatol 2020;5:16. DOI: 10.21037/TGH.2019.09.08.
  11. World Health Organisation. Obesity and overweight. Accessed November 24, 2020. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.
  12. di Cesare M, Bentham J, Stevens GA, et al. Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. The Lancet 2016;387(10026):1377–1396. DOI: 10.1016/S0140-6736(16)30054-X.
  13. Dai H, Alsalhe TA, Chalghaf N, et al. The global burden of disease attributable to high body mass index in 195 countries and territories, 1990–2017: an analysis of the Global burden of disease study. PLoS Med 2020;17(7). DOI: 10.1371/journal.pmed.1003198.
  14. Fan JG, Kim SU, Wong VWS. New trends on obesity and NAFLD in Asia. J Hepatol 2017;67(4):862–873. DOI: 10.1016/j.jhep.2017. 06.003.
  15. Pradeepa R, Anjana R, Joshi S, et al. Prevalence of generalized & abdominal obesity in urban & rural India- the ICMR-INDIAB study (phase-I) [ICMR-INDIAB-3]. Indian J Med Res 2015;142(2):139–150. DOI: 10.4103/0971-5916.164234.
  16. Sayiner M, Koenig A, Henry L, et al. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world. Clin Liver Dis 2016;20(2):205–214. DOI: 10.1016/j.cld.2015.10.001.
  17. Duseja A, Singh SP, Saraswat VA, et al. Non-alcoholic fatty liver disease and metabolic syndrome-position paper of the Indian national association for the study of the liver, endocrine society of India, Indian college of cardiology and Indian society of gastroenterology. J Clin Exp Hepatol 2015;5(1):51–68. DOI: 10.1016/j.jceh.2015.02.006.
  18. Duseja A, Najmy S, Sachdev S, et al. High prevalence of non-alcoholic fatty liver disease among healthy male blood donors of urban India. JGH Open 2019;3(2):133–139. DOI: 10.1002/jgh3.12117.
  19. Duseja A, Das A, Das R, et al. The clinicopathological profile of Indian patients with nonalcoholic fatty liver disease (NAFLD) is different from that in the west. Dig Dis Sci 2007;52(9):2368–2374. DOI: 10.1007/s10620-006-9136-y.
  20. Duseja A, Das A, Dhiman RK, et al. Indian patients with nonalcoholic fatty liver disease presenting with raised transaminases are different at presentation. World J Gastroenterol 2007;13(4):649–650. DOI: 10.3748/wjg.v13.i4.649.
  21. Madan K, Batra Y, Gupta SD, et al. Non-alcoholic fatty liver disease may not be a severe disease at presentation among Asian Indians. World J Gastroenterol: WJG 2006;12(21):3400. DOI: 10.3748/WJG.V12.I21.3400.
  22. Rastogi A, Shasthry SM, Agarwal A, et al. Non-alcoholic fatty liver disease – histological scoring systems: a large cohort single-center, evaluation study. APMIS 2017;125(11):962–973. DOI: 10.1111/apm.12742.
  23. Schuster S, Cabrera D, Arrese M, et al. Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol 2018;15(6):349–364. DOI: 10.1038/s41575-018-0009-6.
  24. De A, Duseja A. Natural history of simple steatosis or nonalcoholic fatty liver. J Clin Exp Hepatol 2020;10(3):255–262. DOI: 10.1016/j.jceh.2019.09.005.
  25. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 2010;51(2):679–689. DOI: 10.1002/hep.23280.
  26. Stefan N, Häring HU, Schulze MB. Metabolically healthy obesity: the low-hanging fruit in obesity treatment? Lancet Diabetes Endocrinol 2018;6(3):249–258. DOI: 10.1016/S2213-8587(17)30292-9.
  27. Young S, Tariq R, Provenza J, et al. Prevalence and profile of nonalcoholic fatty liver disease in lean adults: Systematic review and meta-analysis. Hepatol Communicat 2020;4(7):953–972. DOI: 10.1002/hep4.1519.
  28. Lonardo A, Mantovani A, Lugari S, et al. Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity. Ann Hepatol 2020;19(4):359–366. DOI: 10.1016/j.aohep.2020.03.001.
  29. Ouchi N, Parker JL, Lugus JJ, et al. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011;11(2):85–97. DOI: 10.1038/nri2921.
  30. de Heredia FP, Gómez-Martínez S, Marcos A. Chronic and degenerative diseases: obesity, inflammation and the immune system. In: Proceedings of the Nutrition Society, vol. 71. Cambridge University Press; 2012. pp. 332–338. DOI: 10.1017/S0029665112000092.
  31. Hiuge-Shimizu A, Kishida K, Funahashi T, et al. Absolute value of visceral fat area measured on computed tomography scans and obesity-related cardiovascular risk factors in large-scale Japanese general population (the VACATION-J study). Ann Med 2012;44(1):82–92. DOI: 10.3109/07853890.2010.526138.
  32. Virtue S, Vidal-Puig A. It's not how fat you are, it's what you do with it that counts. PLoS Biol 2008;6(9):1819–1823. DOI: 10.1371/journal.pbio.0060237.
  33. Pellegrinelli V, Carobbio S, Vidal-Puig A. Adipose tissue plasticity: how fat depots respond differently to pathophysiological cues. Diabetologia 2016;59(S):1075–1088. DOI: 10.1007/s00125-016-3933-4.
  34. Stefan N, Schick F, Häring HU. Causes, characteristics, and consequences of metabolically unhealthy normal weight in humans. Cell Metab 2017;26(2):292–300. DOI: 10.1016/j.cmet.2017.07.008.
  35. Lotta LA, Gulati P, Day FR, et al. Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. Nat Genet 2017;49(1):17–26. DOI: 10.1038/ng.3714.
  36. Misra A, Misra R, Wijesuriya M, et al. The metabolic syndrome in South Asians: continuing escalation and possible solutions. Indian J Med Res 2007;125(3):345–354.
  37. Ross R, Neeland IJ, Yamashita S, et al. Waist circumference as a vital sign in clinical practice: a consensus statement from the IAS and ICCR working group on visceral obesity. Nat Rev Endocrinol 2020;16(3):177–189. DOI: 10.1038/s41574-019-0310-7.
  38. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002;123(3):745–750. DOI: 10.1053/gast.2002.35354.
  39. Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol 2017;66(5):1022–1030. DOI: 10.1016/j.jhep.2016.12.022.
  40. Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 2017;65(5):1557–1565. DOI: 10.1002/hep.29085.
  41. Manuel Echevarría J, León P, Pozo F, et al. EASL-ALEH clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015;63(1):237–264. DOI: 10.1016/j.jhep.2015.04.006.
  42. Wong VWS, Adams LA, de Lédinghen V, et al. Noninvasive biomarkers in NAFLD and NASH — current progress and future promise. Nat Rev Gastroenterol Hepatol 2018;15(8):461–478. DOI: 10.1038/s41575-018-0014-9.
  43. Kwok R, Tse Y-K, Wong GL-H, et al. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease - the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther 2014;39(3):254–269. DOI: 10.1111/apt.12569.
  44. Wong VWS, Vergniol J, Wong GLH, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010;51(2):454–462. DOI: 10.1002/hep.23312.
  45. Wong VWS, Vergniol J, Wong GLH, et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2012;107(12):1862–1871. DOI: 10.1038/ajg.2012.331.
  46. Wong VWS, Irles M, Wong GLH, et al. Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease. Gut 2019;68(11):2057–2064. DOI: 10.1136/gutjnl-2018-317334.
  47. Friedrich-Rust M, Poynard T, Castera L. Critical comparison of elastography methods to assess chronic liver disease. Nat Rev Gastroenterol Hepatol 2016;13(7):402–411. DOI: 10.1038/nrgastro.2016.86.
  48. Newsome PN, Sasso M, Deeks JJ, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol 2020;5(4):362–373. DOI: 10.1016/S2468-1253(19)30383-8.
  49. Dongiovanni P, Petta S, Mannisto V, et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol 2015;63(3):705–712. DOI: 10.1016/j.jhep.2015.05.006.
  50. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015;149(2):367–378.e5. DOI: 10.1053/j.gastro.2015.04.005.
  51. Glass LM, Dickson RC, Anderson JC, et al. Total body weight loss of ≥10 % is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis. Dig Dis Sci 2015;60(4):1024–1030. DOI: 10.1007/s10620-014-3380-3.
  52. Wu T, Gao X, Chen M, et al. Long-term effectiveness of diet-plus-exercise interventions vs. Diet-only interventions for weight loss: a meta-analysis: obesity management. Obes Rev 2009;10(3):313–323. DOI: 10.1111/j.1467-789X.2008.00547.x.
  53. Sung KC, Ryu S, Lee JY, et al. Effect of exercise on the development of new fatty liver and the resolution of existing fatty liver. J Hepatol 2016;65(4):791–797. DOI: 10.1016/j.jhep.2016.05.026.
  54. Schweitzer GG, Klein S. Exercise and NAFLD: Is it worth the effort? Hepatology 2017;66(5):1691–1694. DOI: 10.1002/hep.29356.
  55. Younossi Z, Loomba R, Rinella M, et al. Current and future therapeutic regimens for Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Hepatology 2017;777(5):1–36. DOI: 10.1002/hep.
  56. Hashida R, Kawaguchi T, Bekki M, et al. Aerobic vs. Resistance exercise in non-alcoholic fatty liver disease: a systematic review. J Hepatol 2017;66(1):142–152. DOI: 10.1016/j.jhep.2016.08.023.
  57. Ma J, Fox CS, Jacques PF, et al. Sugar-sweetened beverage, diet soda, and fatty liver disease in the Framingham heart study cohorts. J Hepatol 2015;63(2):462–469. DOI: 10.1016/j.jhep.2015.03.032.
  58. Abdelmalek MF, Suzuki A, Guy C, et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 2010;51(6):1961–1971. DOI: 10.1002/hep.23535.
  59. Scorletti E, Bhatia L, Mccormick KG, et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the WELCOME* study. Hepatology 2014;60(4):1211–1221. DOI: 10.1002/hep.27289.
  60. Sanyal AJ, Abdelmalek MF, Suzuki A, et al. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 triaL. Gastroenterology 2014;147(2). DOI: 10.1053/j.gastro.2014.04.046.
  61. Argo CK, Patrie JT, Lackner C, et al. Effects of n-3 fish oil on metabolic and histological parameters in NASH: A double-blind, randomized, placebo-controlled trial. J Hepatol 2015;62(1):190–197. DOI: 10.1016/j.jhep.2014.08.036.
  62. Brunner KT, Henneberg CJ, Wilechansky RM, et al. Nonalcoholic fatty liver disease and obesity treatment. Curr Obes Rep 2019;8(3):220–228. DOI: 10.1007/s13679-019-00345-1.
  63. Ryan MC, Itsiopoulos C, Thodis T, et al. The mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol 2013;59(1):138–143. DOI: 10.1016/j.jhep.2013.02.012.
  64. Chitturi S, Wong VW-S, Chan W-K, et al. The Asia-pacific working party on Non-alcoholic fatty liver disease guidelines 2017-part 2: management and special groups. J Gastroenterol Hepatol 2018;33(1):86–98. DOI: 10.1111/jgh.13856.
  65. Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. The Lancet 2016;387(10019):679–690. DOI: 10.1016/S0140-6736(15)00803-X.
  66. Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Eng J Med, Published online November 13 2020. NEJMoa2028395. DOI: 10.1056/NEJMoa2028395.
  67. Zelber–Sagi S, Kessler A, Brazowsky E, et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006;4(5):639–644. DOI: 10.1016/j.cgh.2006. 02.004.
  68. Fakhry TK, Mhaskar R, Schwitalla T, et al. Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis. Surg Obes Relat Dis 2019;15(3):502–511. DOI: 10.1016/j.soard.2018.12.002.
  69. van Baar ACG, Beuers U, Wong K, et al. Endoscopic duodenal mucosal resurfacing improves glycaemic and hepatic indices in type 2 diabetes: 6-month multicentre results. JHEP Reports 2019;1(6):429–437. DOI: 10.1016/j.jhepr.2019.10.006.
  70. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Eng J Med 2010;362(18):1675–1685. DOI: 10.1056/nejmoa0907929.
  71. Sarin S, Sharma M, Koradia P, et al. A prospective, multi-center, double-blind, randomized trial of saroglitazar 4 mg versus placebo in patients with non-alcoholic steatohepatitis (EVIDENCES II). Hepatol Int 2020;14(s1):S326.
  72. Gawrieh S, Loo NM, Mohseni R, et al. A phase 2, prospective, multicenter, double-blind, randomized study of saroglitazar magnesium 1 mg, 2 mg or 4 mg versus placebo in patients with nonalcoholic fatty liver disease and/or nonalcoholic steatohepatitis (EVIDENCES IV). Hepatology 2019;70(s6):1484–1485A.
  73. Carias S, Castellanos AL, Vilchez V, et al. Nonalcoholic steatohepatitis is strongly associated with sarcopenic obesity in patients with cirrhosis undergoing liver transplant evaluation. J Gastroenterol Hepatol (Australia) 2016;31(3):628–633. DOI: 10.1111/jgh.13166.
  74. Merli M, Berzigotti A, Zelber-Sagi S, et al. EASL clinical practice guidelines on nutrition in chronic liver disease. J Hepatol 2019;70(1):172–193. DOI: 10.1016/j.jhep.2018.06.024.
  75. Berzigotti A, Albillos A, Villanueva C, et al. Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: the SportDiet study. Hepatology 2017;65(4):1293–1305. DOI: 10.1002/hep.28992.
  76. Rebibo L, Gerin O, Verhaeghe P, et al. Laparoscopic sleeve gastrectomy in patients with NASH-related cirrhosis: a case-matched study. Surg Obes Relat Dis 2014;10(3):405–410. DOI: 10.1016/j.soard.2013. 09.015.
  77. Choudhary NS, Puri R, Saraf N, et al. Intragastric balloon as a novel modality for weight loss in patients with cirrhosis and morbid obesity awaiting liver transplantation. Indian J Gastroenterol 2016;35(2):113–116. DOI: 10.1007/s12664-016-0643-2.
  78. Vilar-Gomez E, Vuppalanchi R, Desai AP, et al. Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. Aliment Pharmacol Therapeut 2019;50(3):317–328. DOI: 10.1111/apt.15331.
  79. Vilar-Gomez E, Vuppalanchi R, Gawrieh S, et al. Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis. Hepatology 2020;71(2):495–509. DOI: 10.1002/hep.30368.
  80. Haldar D, Kern B, Hodson J, et al. Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European liver transplant registry study. J Hepatol 2019;71(2):313–322. DOI: 10.1016/j.jhep.2019.04.011.
  81. Saab S, Lalezari D, Pruthi P, et al. The impact of obesity on patient survival in liver transplant recipients: a meta-analysis. Liver Int 2015;35(1):164–170. DOI: 10.1111/liv.12431.
  82. Younossi Z, Ratziu V, Loomba R, et al. GS-06-positive results from REGENERATE: a phase 3 international, randomized, placebo-controlled study evaluating obeticholic acid treatment for NASH. J Hepatol 2019;70(1):e5. DOI: 10.1016/S0618-8278(19) 30006-4.
  83. Harrison SA, Wong VWS, Okanoue T, et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials. J Hepatol 2020;73(1):26–39. DOI: 10.1016/j.jhep.2020.02.027..
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.